GC Therapeutics Adds Industry Veterans Kai-Hsin Chang and Azadeh Golipour to Leadership Team
GC Therapeutics (GCTx), a trailblazing biotechnology company advancing innovative induced pluripotent stem cell (iPSC)-based therapies, today announced the expansion of its leadership team with the appointments of two distinguished industry leaders. Dr. Kai-Hsin Chang, Ph.D., a former senior drug development executive at Editas Medicine, joins as Senior Vice President and Head of Drug Development. Dr. Azadeh Golipour, Ph.D., previously a senior operations leader at AVROBIO, has been appointed Senior Vice President and Head of Technical Operations.
These strategic hires mark a significant step in GC Therapeutics’ mission to revolutionize cell therapy development and accelerate its pipeline of novel therapies powered by its proprietary TFome™ platform. The company’s platform integrates breakthroughs in synthetic biology, gene editing, and machine learning to streamline the development and manufacturing of scalable, off-the-shelf allogeneic cell therapies.
A Proven Leader in Translational Medicine and Regulatory Strategy
Dr. Kai-Hsin Chang brings extensive experience in drug development, regulatory strategy, and translational medicine. During her time at Editas Medicine, she played a pivotal role in advancing genome-editing programs through critical preclinical and early clinical stages. Her leadership contributed to multiple successful Investigational New Drug (IND) applications and laid the groundwork for several high-impact therapies in the gene-editing space.
At GC Therapeutics, Dr. Chang will oversee the strategic direction and execution of the company’s drug development initiatives, ensuring that its cell therapies move efficiently and safely through regulatory pathways toward commercialization.
“I am excited to join GC Therapeutics at such a pivotal and transformative time,” said Dr. Chang. “The company’s TFome™ platform represents a paradigm shift in cell therapy development, and I look forward to working alongside this visionary team to deliver groundbreaking therapies to patients who currently have limited treatment options.”
Driving Scalable and Innovative Manufacturing
Joining alongside Dr. Chang is Dr. Azadeh Golipour, an expert in technical operations and cell therapy manufacturing. At AVROBIO, she led efforts to build and optimize scalable, GMP-compliant manufacturing platforms critical to the development of gene and cell therapies. Her ability to translate early-stage discoveries into robust, scalable clinical production has earned her recognition across the industry.
In her new role at GC Therapeutics, Dr. Golipour will spearhead the company’s technical operations, including process development, manufacturing, and supply chain strategies. Her mandate is to accelerate the scalable production of GCTx’s therapies, ensuring quality, consistency, and accessibility across various therapeutic indications.
“GC Therapeutics is driving the future of regenerative medicine by combining next-generation science with real-world clinical impact,” said Dr. Golipour. “The company’s differentiated technology, particularly its potential to enable scalable, off-the-shelf allogeneic therapies, opens up new possibilities in how we treat complex diseases. I’m thrilled to contribute to such a mission-driven organization that is committed to reshaping patient care on a global scale.”
Leadership Driving Toward a New Era of Cell Therapy
The appointments of Drs. Chang and Golipour reflect GC Therapeutics’ continued momentum as it moves toward clinical development and scaled manufacturing of its first-in-class therapies. Their deep experience and leadership are expected to play a critical role in advancing the company’s pipeline across key therapeutic areas, including gastrointestinal, neurological, and immunological diseases.
“Azadeh and Kai-Hsin are exceptional additions to our leadership team,” said Dr. Parastoo Khoshakhlagh, CEO and Co-founder of GC Therapeutics. “Their experience in cell and gene therapy development will be instrumental in accelerating our programs and expanding patient access to next-generation cell therapies. Together, we are advancing a future where transformative treatments are not only possible but widely available to those who need them most.”
About GC Therapeutics
Founded in 2019 and headquartered in Cambridge, Massachusetts, GC Therapeutics (GCTx) is a biopharmaceutical company developing scalable, off-the-shelf iPSC-based cell therapies. Its proprietary TFome™ platform combines innovations in synthetic biology, gene editing, cell engineering, and machine learning to overcome the challenges associated with traditional cell therapy development and manufacturing.
GCTx’s mission is to democratize access to cell therapies by making them safer, more effective, and widely available. The company’s initial focus includes developing therapies for conditions in the gastrointestinal, neurological, and immunological space. To date, GC Therapeutics has raised $75 million in funding from leading life science investors.
